Company: HRTX
Filing Date: 2025-09-09
Form Type: S-3
Source: 0000950170-25-113830
Chunk: 27

Company: HERON THERAPEUTICS, INC. /DE/
Filing Date: 2025-09-09
Form: S-3
Chunk 27
---
, (ii) 5,241,410 shares of Common Stock issuable upon the conversion of our Series A Convertible Preferred Stock issued to certain purchasers pursuant to the Purchase Agreement and (iii) 19,444,444 shares of Common Stock issuable upon the conversion of the Notes issued to a fund affiliated with Rubric pursuant to the Note Purchase Agreement. |
| Common Stock outstanding prior to this offering        |     | 183,314,667 shares as of September 3, 2025.                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Common Stock to be outstanding after this offering     |     | 208,000,521 shares (assuming the conversion of all Series A Convertible Preferred issued pursuant to the Purchase Agreement and the conversion of the Notes issued pursuant to the Note Purchase Agreement upon Stockholder Approval).                                                                                                                                                                                                                                                                        |
| Use of proceeds                                        |     | We will not receive any proceeds from the sale or other disposition of the shares of Common Stock offered hereby.                                                                                                                                                                                                                                                                                                                                                                                             |
| Risk factors                                           |     | Investing in our Common Stock involves a high degree of risk. See “Risk Factors” beginning on page 15 of this prospectus, and any other risk factors described in the documents incorporated by reference herein, for a discussion of factors that you should carefully consider before deciding to invest in our Common Stock.                                                                                                                                                                               |
| Nasdaq Capital Market symbol                           |     | Our common stock is listed on The Nasdaq Capital Market under the symbol “HRTX.”                                                                                                                                                                                                                                                                                                                                                                                                                              |

When we refer to the Selling Stockholders in this prospectus, we are referring to the entities and individuals named in this prospectus as the Selling Stockholders and, as applicable, any pledgee, assignee, permitted transferee or other successor-in-interest selling shares received after the date of this prospectus from the Selling Stockholders as a pledge, assignment or other transfer that may be identified in a supplement to this prospectus or, if required, a post-effective amendment to the registration statement of which this prospectus is a part.

<div align='center'>14

RISK FACTORS</div>

Investing in our Common Stock involves a high degree of risk. You should carefully consider the risks, uncertainties and assumptions contained in this prospectus and discussed under the heading “Risk Factors” included in our Annual Report on Form 10-K for the year ended December 31, 2024, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC and are incorporate herein by reference